Exploring blood clotting mechanisms in COVID-19 patients
Cellular Effects of SARS-CoV-2 in Mediating Thrombotic Susceptibility
This study is trying to understand how blood clotting works in hospitalized COVID-19 patients by looking at their blood samples over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | University of Iowa Academic / other |
| Locations | 1 site (Iowa City, Iowa) |
| Trial ID | NCT05334615 on ClinicalTrials.gov |
What this trial studies
This observational study at the University of Iowa aims to investigate the mechanisms behind enhanced thrombin generation in hospitalized COVID-19 patients. By collecting blood samples from patients at enrollment and weekly for up to 30 days, the study will analyze the activation of blood cells and their role in coagulopathy associated with COVID-19. The research builds on previous findings that suggest a link between COVID-19 and increased thrombin generation, which may contribute to severe complications. The longitudinal cohort design will provide insights into the duration and nature of these changes during hospitalization.
Who should consider this trial
Good fit: Ideal candidates include hospitalized adults aged 18 and older with confirmed COVID-19 or incidental COVID-19 infections.
Not a fit: Patients with a history of bleeding disorders, active cancer, or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of coagulopathy in COVID-19 patients, potentially improving patient outcomes.
How similar studies have performed: Other studies have shown potential links between COVID-19 and coagulopathy, but this specific mechanistic exploration is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria Subjects must meet all inclusion criteria in one of the following three categories: 1. Acute COVID-19 * Hospital admission for management of symptoms related to COVID-19 * Laboratory confirmed infection with SARS-CoV-2 by either PCR or antigen testing within 4 weeks of hospital admission * Age ≥18 years 2. Incidental COVID-19 * Hospital admission for indications unrelated to COVID-19 who are incidentally found to have infection with SARS-CoV-2 * Age ≥18 years 3. Acute influenza * Hospital admission for clinical management of symptoms related to influenza * Laboratory confirmed infection with influenza A or influenza B within 4 weeks of hospital admission * Negative testing for SARS-CoV-2 * Age ≥18 years Exclusion criteria * Current pregnancy * Prisoner * History of a bleeding disorder * Active cancer
Where this trial is running
Iowa City, Iowa
- University of Iowa Health Care — Iowa City, Iowa, United States (Recruiting)
Study contacts
- Study coordinator: Steven Lentz, MD, PhD
- Email: steven-lentz@uiowa.edu
- Phone: +1 319 356 4048
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.